Why is Inhibrx Biosciences, Inc. ?
1
Positive results in Sep 25
- NET SALES(HY) At USD 1.3 MM has Grown at 1,200%
- NET PROFIT(HY) Higher at USD -63.91 MM
- RAW MATERIAL COST(Y) Fallen by 0% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 307.75%, its profits have fallen by -38%
3
Rising Promoter Confidence
- Promoters have increased their stake in the company by 0.81% over the previous quarter and currently hold 11.85% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
4
Market Beating Performance
- The stock has generated a return of 307.75% in the last 1 year, much higher than market (S&P 500) returns of 11.87%
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
No Data Found
Quality key factors
Factor
Value
Sales Growth (5y)
-69.80%
EBIT Growth (5y)
-175.30%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
89.13%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
27.35
EV to EBIT
-6.21
EV to EBITDA
-6.32
EV to Capital Employed
-67.86
EV to Sales
683.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-421.09%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
Technical Movement
8What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -131.92 MM
NET PROFIT(HY)
Higher at USD -66.28 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 6.5 times
-12What is not working for the Company
ROCE(HY)
Lowest at -354.69%
DEBT-EQUITY RATIO
(HY)
Highest at -91.47 %
INTEREST(Q)
Highest at USD 3.51 MM
Here's what is working for Inhibrx Biosciences, Inc.
Operating Cash Flow
Highest at USD -131.92 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD -66.28 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 6.5 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Inhibrx Biosciences, Inc.
Interest
Highest at USD 3.51 MM
in the last five periods and Increased by 10.17% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at -91.47 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio






